|
Mechanism50S subunit inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date21 Dec 2000 |
比较Duac每日一次凝胶与克林霉素磷酸酯凝胶治疗轻至中度寻常痤疮有效性和安全性的多中心平行对照临床试验
[Translation] A multicenter parallel controlled clinical trial comparing the efficacy and safety of Duac once-daily gel and clindamycin phosphate gel in the treatment of mild to moderate acne vulgaris
主要目的 评价Duac 每日一次凝胶与克林霉素磷酸酯凝胶局部治疗轻至中度寻常痤疮的有效性。 次要目的 评价Duac每日一次凝胶与克林霉素磷酸酯凝胶局部治疗轻至中度寻常痤疮的安全性和耐受性。
[Translation] Primary objective To evaluate the effectiveness of Duac once-daily gel versus topical clindamycin phosphate gel in the treatment of mild to moderate acne vulgaris. Secondary objective To evaluate the safety and tolerability of Duac once-daily gel versus topical clindamycin phosphate gel in the treatment of mild to moderate acne vulgaris.
100 Clinical Results associated with Famalink (Shanghai) Medical Consulting Service Co., Ltd.
0 Patents (Medical) associated with Famalink (Shanghai) Medical Consulting Service Co., Ltd.
100 Deals associated with Famalink (Shanghai) Medical Consulting Service Co., Ltd.
100 Translational Medicine associated with Famalink (Shanghai) Medical Consulting Service Co., Ltd.